Business Context and Reporting Period
This Form 8-K reports on a special meeting of stockholders held by Penumbra, Inc. on May 6, 2026. The filing details the voting results regarding a proposed merger with Boston Scientific Corporation.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
Stockholders voted on three proposals at the special meeting. The record date was March 26, 2026, with 39,324,084 shares outstanding and 28,665,933 shares present (constituting a quorum).
- Merger Proposal: Approved. Stockholders voted to adopt the Agreement and Plan of Merger with Boston Scientific Corporation.
- Votes For: 28,564,786
- Votes Against: 85,334
- Abstentions: 15,813
- Advisory Compensation Proposal: Approved. Non-binding vote on executive compensation related to the merger.
- Votes For: 27,811,605
- Votes Against: 765,399
- Abstentions: 88,929
- Adjournment Proposal: Received votes but was rendered unnecessary due to the approval of the Merger Proposal.
- Votes For: 27,309,440
- Votes Against: 1,295,803
- Abstentions: 60,690
Outlook, Risks, and Contingencies
While the Merger Proposal was approved, the consummation of the merger remains subject to the satisfaction or waiver of other closing conditions. Key contingencies include:
- Expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
- Receipt of clearances or approvals (or expiration of waiting periods) under antitrust, competition, or foreign investment laws in certain non-U.S. jurisdictions.
Investor Verification Checklist
- Verify the status of regulatory approvals required under the Hart-Scott-Rodino Act and international antitrust laws.
- Confirm the expected closing date of the merger with Boston Scientific Corporation.
- Review the Definitive Proxy Statement (Schedule 14A) filed on April 1, 2026, for detailed terms of the merger agreement and executive compensation.
- Monitor for any subsequent filings regarding the satisfaction of remaining closing conditions.